What MOTS-c is

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA Type-c. It is a 16-amino acid peptide, which makes it small even by peptide standards. What sets it apart from virtually every other compound in the research peptide space is where it comes from: the mitochondrial genome, not nuclear DNA.

Most proteins and peptides the body produces are encoded in nuclear DNA, transcribed and translated through the standard cellular machinery. Mitochondria have their own separate genome, a remnant of the ancient bacterial ancestors from which mitochondria evolved. For a long time, researchers believed this genome encoded only the core proteins needed to run the mitochondria's own respiratory machinery. The discovery that it also encodes signaling peptides like MOTS-c opened a new area of biology.

MOTS-c was first described in research published in 2015 by Lee, Kim, and colleagues. In that initial work, the peptide was found to be produced primarily in mitochondria, secreted into the bloodstream, and capable of acting on distant tissues including skeletal muscle and the liver. In rodent models, injected MOTS-c improved insulin sensitivity and reduced weight gain when animals were fed a high-fat diet. That combination of findings attracted significant scientific attention and, in time, commercial interest.

Regulatory status

MOTS-c has never been an approved drug and has no compounding pathway.

Unlike some research peptides that exist in regulatory gray areas because of prior approvals or established compounding histories, MOTS-c has never held an FDA-approved indication. It is not on any published compounding list maintained by the FDA or USP. Research-labeled MOTS-c is sold for laboratory use only and is not cleared for human administration. Anyone evaluating a vendor selling MOTS-c for human use should understand they are operating entirely outside established regulatory frameworks. This page discusses the compound in the context of understanding the science and the vendor landscape; it does not endorse any particular use.

The mechanism proposed in the research involves MOTS-c acting through the AMPK (AMP-activated protein kinase) pathway, a cellular energy sensor that plays a broad role in glucose metabolism, fatty acid oxidation, and mitochondrial function. AMPK is a well-studied target in metabolic research; the diabetes drug metformin is thought to work partly through AMPK activation. That connection has made MOTS-c's mechanism credible to researchers, though demonstrating that exogenously administered MOTS-c activates the same pathway in humans at meaningful concentrations has not yet been done in controlled trials.

How MOTS-c is discussed and marketed

Research compound vendors and online communities focused on peptides tend to frame MOTS-c in three overlapping areas: metabolic support, exercise performance, and longevity or anti-aging. Here is how each maps to the actual published evidence.

Area 1

Metabolic regulation

The strongest preclinical signal. Rodent studies show MOTS-c reduces insulin resistance, lowers blood glucose on a high-fat diet, and decreases fat accumulation. The mechanism via AMPK activation is mechanistically plausible. No controlled human intervention trials have replicated these findings in humans.

Preclinical (rodent)
Area 2

Exercise performance

Rodent data shows increased endurance following MOTS-c administration. Human observational studies have measured rising endogenous MOTS-c after exercise, but that is a very different finding from showing that administering MOTS-c improves human athletic performance. The two are often conflated in marketing.

Preclinical / observational
Area 3

Aging and longevity

Some studies have measured lower circulating MOTS-c in older adults compared to younger cohorts. Whether restoring levels through exogenous administration produces any meaningful effect in humans has not been studied. The aging connection is a hypothesis, not an established clinical application.

Emerging / hypothesis
Area 4

Insulin sensitivity

This is the most cited outcome from the original MOTS-c research. Rodent models with diet-induced insulin resistance showed improvement after MOTS-c treatment. Researchers have pointed to this as a potential future therapeutic target for metabolic disease. No human clinical trials for insulin resistance have been completed or published.

Preclinical only

The honest summary is this: MOTS-c has one of the more scientifically interesting origin stories of any compound in the research peptide market, and the preclinical metabolic signals are real and peer-reviewed. What is missing is human interventional data. Marketing that presents the rodent outcomes as established human benefits overstates what the evidence actually shows.

How to evaluate a vendor selling MOTS-c

MOTS-c is a short peptide that can be synthesized using standard solid-phase peptide synthesis methods. That means production is technically accessible to a wide range of manufacturers, including those with limited quality controls. The research compound market for MOTS-c is particularly difficult to evaluate because the compound has no compounding standard, no approved reference formulation, and no pharmacopoeial monograph to benchmark purity against.

Vendor evaluation checklist

  • Third-party COA from an accredited lab: The certificate of analysis should come from an independent laboratory with ISO 17025 accreditation or equivalent. The lab name, accreditation number, and contact details should be publicly verifiable. In-house COAs from the vendor's own lab provide minimal assurance.
  • Mass spectrometry confirmation: For a 16-amino acid peptide, mass spec (HRMS or LC-MS/MS) is the appropriate method to confirm molecular identity. HPLC purity alone tells you how much of something is there; it does not confirm that the something is actually MOTS-c. Both tests together are a meaningful minimum.
  • Batch traceability: The COA should match the specific lot or batch number on the product you receive. Undated or batch-unlinked COAs offer little meaningful assurance about what is in your vial.
  • Claims review: A vendor making treatment claims or suggesting MOTS-c has proven human benefits is marketing beyond what the published evidence supports and beyond the legal scope of a research-compound vendor. Strong outcome claims are a quality signal in the wrong direction.
  • Research-only labeling honesty: Vendors selling MOTS-c should clearly label it for laboratory research only. Vendors who frame research compound sales as equivalent to or as easy substitutes for medical treatment are not operating transparently.
  • Contact and verification policy: Reputable vendors provide a verifiable business address, accessible customer service, and a clear process for requesting batch documentation. Anonymity or vague contact information is a meaningful red flag in a market with no regulatory backstop.

Affiliate disclosure: The link below is a paid affiliate relationship. We earn a commission if you purchase through it. This relationship did not influence our evaluation of MOTS-c or the vendor criteria above. See our full disclosure policy.

Looking for a vendor that meets these criteria?

We reviewed vendors against the checklist above. The following link goes to a vendor whose COA documentation and batch traceability we found consistent with the standards described in this article. We have not evaluated the product itself, and this is not a clinical recommendation.

View vendor COA documentation Affiliate link

MOTS-c is often grouped with other compounds studied for metabolic or mitochondrial effects. The three below are among the most frequently discussed in overlapping research and market contexts.

5-Amino-1MQ

A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in fat cell differentiation. Studied for metabolic effects in rodent models. Not a peptide by structure, but frequently grouped with research compounds in the metabolic category.

Read 5-Amino-1MQ explainer →
SS-31

A mitochondria-targeted antioxidant peptide (also called Elamipretide) that works by binding cardiolipin in the inner mitochondrial membrane. Has a more developed clinical research record than MOTS-c, including human trials in heart failure. Related by its mitochondrial focus, distinct in mechanism and evidence base.

Read SS-31 explainer →
Tesamorelin

A GHRH analog with FDA approval for HIV-associated lipodystrophy. Relevant here because it is one of the few metabolically oriented peptides with actual controlled human trial data and an approved indication. A useful evidence-level benchmark for the MOTS-c research gap.

Read Tesamorelin explainer →

Sources

  1. 1 Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed
  2. 2 Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed
  3. 3 Kim SJ, Xiao J, Wan J, et al. Mitochondrially derived peptides as novel regulators of metabolism. J Physiol. 2017;595(21):6613-6621. PubMed
  4. 4 Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. PubMed
  5. 5 Lu H, Tang S, Xue C, et al. Mitochondrial-derived peptide MOTS-c increases adipose thermogenic activation to promote cold adaptation. Int J Mol Sci. 2019;20(10):2456. PubMed
  6. 6 FDA. Human drug compounding. Regulatory information on sections 503A and 503B compounding. FDA.gov
  7. 7 FDA. Drugs@FDA: FDA-Approved Drugs. Search for MOTS-c returns no approved products. FDA Access Data

Frequently asked questions

What is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded within the mitochondrial genome, specifically the 12S ribosomal RNA gene. It is part of a class called mitochondrial-derived peptides. Animal studies published from 2015 onward found that it plays a role in metabolic regulation, particularly insulin signaling and the cellular response to exercise. It is distinct from nuclear-encoded peptides because its genetic origin is the mitochondrion rather than the cell nucleus. For research purposes it is produced through standard solid-phase peptide synthesis.
What are MOTS-c benefits?
In preclinical models, primarily rodent studies, MOTS-c has been associated with improved insulin sensitivity, reduced weight gain on a high-fat diet, enhanced exercise endurance, and effects on cellular energy metabolism through the AMPK pathway. Observational human studies have found that circulating MOTS-c levels rise after exercise and may decline with age. These findings are genuine and peer-reviewed. What has not been established is whether administering exogenous MOTS-c to humans produces any of these outcomes. There are no published controlled human intervention trials. Claims about MOTS-c benefits in humans are extrapolations from animal data, and that distinction matters when evaluating marketing.
Is MOTS-c legal?
MOTS-c is not FDA-approved for any human use. It has never held an approved indication, and it is not part of any established compounding framework. It circulates in the research compound market labeled for laboratory use only. Purchasing it in that context is legally distinct from purchasing a prescription drug, but it is also legally distinct from purchasing an approved or regulated product. The legal landscape around research peptides is complex and varies by jurisdiction. This page does not constitute legal or medical advice; consult a licensed professional for guidance relevant to your situation.
How does MOTS-c differ from other metabolic peptides?
The primary distinction is its origin. MOTS-c is one of the only known human peptides encoded in the mitochondrial genome rather than nuclear DNA, which makes it scientifically unusual and of genuine interest to researchers studying mitochondrial biology and aging. Practically, that origin does not change how it is synthesized for research (standard solid-phase synthesis) or sold. Its evidence base is also substantially more preclinical than compounds like tesamorelin, which has a completed FDA-approved indication in humans, or sermorelin, which had a prior approval. MOTS-c is genuinely earlier in its research trajectory than most compounds in the same market.
What do researchers study MOTS-c for?
Published peer-reviewed research has focused on three areas: metabolic regulation (especially insulin signaling and glucose uptake in muscle and liver cells), exercise physiology (endogenous MOTS-c rises in the bloodstream following physical activity in humans), and aging biology (some studies find lower circulating MOTS-c in older adults, with proposed links to age-related metabolic decline). All three are preliminary. The exercise finding is observational rather than interventional, meaning researchers measured what happens to naturally produced MOTS-c after exercise, not what happens when MOTS-c is administered before exercise. That distinction is important when evaluating performance-related marketing claims.